Relmada Therapeutics, Inc. SEC filings RLMD
Relmada Therapeutics, Inc. has 606 filings in SEC EDGAR's recent list, going back to Nov 13, 2012. Its latest annual report, Form 10-K, was filed on Mar 19, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 8, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 17, 2026 | — |
| DEF 14A | Proxy statement | Apr 17, 2026 | May 27, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 6, 2026 | Apr 6, 2026 |
| DEFA14A | Additional proxy material | Apr 11, 2025 | — |
| DEF 14A | Proxy statement | Apr 11, 2025 | May 23, 2025 |
| DEFA14A | Additional proxy material | Apr 9, 2024 | — |
| DEF 14A | Proxy statement | Apr 9, 2024 | May 24, 2024 |
| DEFA14A | Additional proxy material | Mar 31, 2023 | — |
| DEF 14A | Proxy statement | Mar 31, 2023 | May 25, 2023 |
| DEF 14A | Proxy statement | Apr 11, 2022 | May 25, 2022 |
| PRE 14A | Preliminary proxy statement | Mar 31, 2022 | Mar 31, 2022 |
| DEF 14A | Proxy statement | Mar 31, 2021 | May 20, 2021 |
| DEFA14A | Additional proxy material | Feb 28, 2020 | — |
| DEF 14A | Proxy statement | Jan 31, 2020 | Mar 6, 2020 |
| DEF 14A | Proxy statement | Jan 9, 2019 | Feb 27, 2019 |
| PRE 14A | Preliminary proxy statement | Dec 21, 2018 | Dec 21, 2018 |
| DEF 14A | Proxy statement | Dec 15, 2017 | Dec 18, 2017 |
| DEF 14A | Proxy statement | Dec 30, 2016 | Jan 27, 2016 |
| DEFA14A | Additional proxy material | Dec 28, 2015 | — |
| DEFA14A | Additional proxy material | Dec 23, 2015 | — |
| DEFA14A | Additional proxy material | Dec 21, 2015 | — |
| DEFA14A | Additional proxy material | Dec 15, 2015 | — |
| DEFA14A | Additional proxy material | Dec 14, 2015 | — |
| DEFA14A | Additional proxy material | Dec 14, 2015 | — |
| DEFA14A | Additional proxy material | Dec 11, 2015 | — |
| DEFA14A | Additional proxy material | Dec 11, 2015 | — |
| DEFA14A | Additional proxy material | Dec 10, 2015 | — |
| DEFA14A | Additional proxy material | Dec 9, 2015 | — |
| DEFA14A | Additional proxy material | Dec 9, 2015 | — |
| DEFA14A | Additional proxy material | Dec 7, 2015 | — |
| DEF 14A | Proxy statement | Nov 27, 2015 | Dec 30, 2015 |
| DEF 14A | Proxy statement | Nov 17, 2014 | Dec 18, 2014 |
| PRE 14A | Preliminary proxy statement | Nov 5, 2014 | Nov 5, 2014 |
Showing 33 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RLMD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Coral Gables, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1553643
- Former names
- CAMP NINE, INC. (until Jul 14, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.